Page last updated: 2024-10-22

am 251 and Neuralgia

am 251 has been researched along with Neuralgia in 11 studies

AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.

Neuralgia: Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.

Research Excerpts

ExcerptRelevanceReference
"Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity."5.51Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019)
"AM404 attenuated mechanical and cold hyperalgesia with minimal effects on motor coordination."1.62Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model. ( Hara, K; Haranishi, Y; Terada, T, 2021)
"Seven days of treatment with CBD reduced mechanical allodynia, decreased anxiety-like behavior, and normalized 5-HT activity."1.51Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. ( Aboud, M; Comai, S; De Gregorio, D; Enns, J; Gobbi, G; Lopez-Canul, M; Maione, S; McLaughlin, RJ; Ochoa-Sanchez, R; Posa, L, 2019)
"Paclitaxel produced mechanical and cold allodynia without altering nestlet shredding or marble burying behaviors."1.48Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. ( Hohmann, AG; Iyer, V; Makriyannis, A; Saberi, SA; Slivicki, RA; Vemuri, VK, 2018)
"MCS reversed mechanical hyperalgesia, inhibited astrocyte and microglial activity, decreased proinflammatory cytokine staining, enhanced CB2 staining, and downregulated P2X4 receptors in the DHSC ipsilateral to sciatic injury."1.42The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain? ( Fonoff, ET; Lopes, PS; Pagano, RL; Silva, GD, 2015)
"Mechanical allodynia and thermal hyperalgesia were evaluated in 436 male C57BL/6, cnr1KO and cnr2KO mice in the presence or absence of cannabinoid CB₁ (AM251) or CB₂ (AM630) receptor antagonists in a mouse model of neuropathic pain."1.40Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. ( Beaulieu, P; Bouchard, JF; Charron, S; Desroches, J, 2014)
"Models of neuropathic pain are associated with elevated spinal levels of endocannabinoids (ECs) and altered expression of cannabinoid receptors on primary sensory afferents and post-synaptic cells in the spinal cord."1.36Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. ( Barrett, DA; Chapman, V; de Lago, E; Fernández-Ruiz, J; Gray, RA; Jhaveri, MD; Kendall, DA; Richardson, D; Sagar, DR, 2010)
"Thermal hyperalgesia was significantly ameliorated in a dose-dependent manner with systemically administered WIN."1.36Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain. ( Ahmed, MM; Allcock, B; Gerovac, TA; McChesney, S; Miranpuri, GS; Patel, AU; Rajpal, S; Resnick, DK; Sweeney, C; Tilghman, JI, 2010)
"Paracetamol dose-dependently decreased mechanical allodynia and lowered nociceptive scores associated with hyperalgesia testing."1.34The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors. ( Beaulieu, P; Dani, M; Guindon, J; Lambert, C, 2007)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's8 (72.73)24.3611
2020's2 (18.18)2.80

Authors

AuthorsStudies
Haranishi, Y1
Hara, K1
Terada, T1
Malvestio, RB1
Medeiros, P1
Negrini-Ferrari, SE1
Oliveira-Silva, M1
Medeiros, AC1
Padovan, CM1
Luongo, L1
Maione, S2
Coimbra, NC1
de Freitas, RL1
Segat, GC1
Manjavachi, MN1
Matias, DO1
Passos, GF1
Freitas, CS1
Costa, R1
Calixto, JB1
De Gregorio, D1
McLaughlin, RJ1
Posa, L1
Ochoa-Sanchez, R1
Enns, J1
Lopez-Canul, M1
Aboud, M1
Comai, S1
Gobbi, G1
Slivicki, RA1
Saberi, SA1
Iyer, V1
Vemuri, VK1
Makriyannis, A1
Hohmann, AG1
Desroches, J1
Charron, S1
Bouchard, JF1
Beaulieu, P2
Petrenko, AB1
Yamazaki, M1
Sakimura, K1
Kano, M1
Baba, H1
Silva, GD1
Lopes, PS1
Fonoff, ET1
Pagano, RL1
Sagar, DR1
Jhaveri, MD1
Richardson, D1
Gray, RA1
de Lago, E1
Fernández-Ruiz, J1
Barrett, DA1
Kendall, DA1
Chapman, V1
Ahmed, MM1
Rajpal, S1
Sweeney, C1
Gerovac, TA1
Allcock, B1
McChesney, S1
Patel, AU1
Tilghman, JI1
Miranpuri, GS1
Resnick, DK1
Dani, M1
Guindon, J1
Lambert, C1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Dose Controlled Diabetic Neuropathic Pain Study Using Non-Intoxicating Cannabidiol in a Rapidly Dissolvable Sublingual Tablet[NCT04088929]Phase 232 participants (Actual)Interventional2019-09-30Completed
A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT04679545]Phase 250 participants (Anticipated)Interventional2020-12-10Recruiting
Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury[NCT04057456]Phase 3140 participants (Anticipated)Interventional2023-03-01Recruiting
A Randomized, Double-Blind, Placebo-Controlled Trial Using Cannabidiol and Palmitoylethanolamide for the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet[NCT05766969]Phase 1/Phase 252 participants (Anticipated)Interventional2023-06-05Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

11 other studies available for am 251 and Neuralgia

ArticleYear
Inhibitory effect of intrathecally administered AM404, an endocannabinoid reuptake inhibitor, on neuropathic pain in a rat chronic constriction injury model.
    Pharmacological reports : PR, 2021, Volume: 73, Issue:3

    Topics: Animals; Arachidonic Acids; Capsaicin; Constriction; Disease Models, Animal; Endocannabinoids; Hyper

2021
Cannabidiol in the prelimbic cortex modulates the comorbid condition between the chronic neuropathic pain and depression-like behaviour in rats: The role of medial prefrontal cortex 5-HT
    Brain research bulletin, 2021, Volume: 174

    Topics: Animals; Cannabidiol; Chronic Disease; Cobalt; Depression; Limbic System; Microinjections; Neuralgia

2021
Antiallodynic effect of β-caryophyllene on paclitaxel-induced peripheral neuropathy in mice.
    Neuropharmacology, 2017, Volume: 125

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phyto

2017
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain.
    Pain, 2019, Volume: 160, Issue:1

    Topics: Action Potentials; Animals; Anxiety; Cannabidiol; Capsaicin; Disease Models, Animal; Exploratory Beh

2019
Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
    The Journal of pharmacology and experimental therapeutics, 2018, Volume: 367, Issue:3

    Topics: Amidohydrolases; Analgesics, Opioid; Animals; Antineoplastic Agents; Arachidonic Acids; Benzamides;

2018
Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
    Neuropharmacology, 2014, Volume: 77

    Topics: Animals; Arachidonic Acids; Behavior, Animal; Endocannabinoids; Glycerides; Hyperalgesia; Male; Mice

2014
Augmented tonic pain-related behavior in knockout mice lacking monoacylglycerol lipase, a major degrading enzyme for the endocannabinoid 2-arachidonoylglycerol.
    Behavioural brain research, 2014, Sep-01, Volume: 271

    Topics: Animals; Arachidonic Acids; Benzodioxoles; Cannabinoid Receptor Modulators; Endocannabinoids; Glycer

2014
The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain?
    Journal of neuroinflammation, 2015, Jan-20, Volume: 12

    Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents; Calcium-Binding Proteins; Cytokines; Deep B

2015
Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
    The European journal of neuroscience, 2010, Volume: 31, Issue:8

    Topics: Anesthesia; Animals; Arachidonic Acids; Camphanes; Cannabinoid Receptor Modulators; Central Nervous

2010
Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
    The spine journal : official journal of the North American Spine Society, 2010, Volume: 10, Issue:12

    Topics: Analgesics; Analysis of Variance; Animals; Benzoxazines; Dose-Response Relationship, Drug; Hot Tempe

2010
The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors.
    European journal of pharmacology, 2007, Nov-14, Volume: 573, Issue:1-3

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arachidonic Acids; Cannabinoid Receptor Antagonist

2007